2026³â 02¿ù 27ÀÏ ±Ý¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Center for Disease Analysis Foundation Receives $7 Million Grant from the John C. Martin Foundation to Support the Polaris Observatory

´º½ºÀÏÀÚ: 2024-11-22

LAFAYETTE, COLO. -- The Center for Disease Analysis (CDA) Foundation announced receipt of a $7 million grant from the John C. Martin Foundation to sustain and expand the Polaris Observatory until the end of 2030.

The Polaris Observatory serves as the definitive source for global data on hepatitis B and C virus (HBV and HCV) burden, providing insights into the prevalence and distribution of these viruses across countries, regions, and globally. It also assists national governments and international organizations in monitoring progress toward the World Health Organization’s (WHO) 2030 elimination targets for HBV and HCV. Annually, the Observatory collaborates with over 1,000 national experts in 120 countries, updating forecasts for each country. Additionally, it offers pro bono support to national governments, assisting them in developing and implementing elimination programs and strategies to fund for their initiatives.

“We are deeply grateful for the John C. Martin Foundation’s unwavering support,” expressed Homie Razavi, Managing Director of the CDA Foundation. “Their initial funding in 2015 catalyzed the establishment of the Polaris Observatory, and their continuous support has enabled us to sustain our work. The Observatory’s programs are supported by a dedicated team of epidemiologists, mathematical modelers, programmers, and decision analysts. The Observatory’s contributions have resulted in nationally funded access to hepatitis screening for 1.7 billion people globally, laboratory testing (24 million people), and treatment (19 million people) as result of recognized value of early detection and treatment. This new grant will facilitate our continued efforts through 2030.”

“On behalf of the John C. Martin Foundation, it is a privilege to support the CDA Foundation in the past decade to service the international hepatitis elimination collaborators. We are grateful for the opportunity to support such an impactful and momentous program,” said Dr. Lillian Lou, President, Program Director of the John C. Martin Foundation (https://thejcmfoundation.org).

CDA Foundation is a nonprofit organization focused on accelerating hepatitis B and C elimination through verified epidemiological data, disease burden and economic impact modeling, intervention strategies, innovative financing, and knowledge-sharing partnerships. It accomplishes these goals through the Polaris Observatory (https://cdafound.org/polaris/).



 Àüü´º½º¸ñ·ÏÀ¸·Î

NetApp Data Platform Powers Data Operations for Super Bowl LX
Concept Medical Begins STARS DAPT Trial With First Patient for Abluminus NP Polymer-Free DES
Research From Lenovo Reveals AI Is Paying Off, Yet Most CIOs Aren¡¯t Ready for What Comes Next
Revolutionizing 5G Network Slice Testing: Industry-First Performance Methodology by Ookla and Ericsson
Parse Biosciences Launches Workflow for Immune Repertoire and Transcriptome Analysis
Copeland Advances AI and Digital Strategy with Acquisition of Bueno Analytics
Vestas Secures 390 MW Offshore Order in South Korea

 

Syngenta to Tackle Global Farm Challenges at WEF, Driving AI Innovatio...
Philip Morris International Opens Dialogue on the Future of Human Cogn...
Crown Bioscience San Diego Lab Earns CAP Accreditation, Expands Clinic...
Axelspace Signs MoU with Ethiopian Company to Address Social Challenge...
Parse Biosciences and Graph Therapeutics Partner to Build Large Functi...
SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing
Innovative Research Unveils Potential of Pharmaceutically Processed Mi...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬银öõ(ÜÄÒ¬ÜØ...
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..